Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS01B
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intratumoral
01
Overview
**AS01B** is GSK's proprietary liposome-based vaccine adjuvant system rather than a standalone antigen-containing vaccine. It combines the immunostimulants 3-O-desacyl-4'-monophosphoryl lipid A (MPL), a detoxified *Salmonella minnesota* lipopolysaccharide derivative and Toll-like receptor 4 agonist, with the *Quillaja saponaria*-derived saponin QS-21 in DOPC and cholesterol liposomes. The formulation promotes transient innate immune activation, antigen-presenting-cell recruitment and activation, and enhanced antigen-specific cellular and humoral immunity. It is a component of the recombinant zoster vaccine Shingrix and has also been evaluated as an adjuvant in investigational infectious-disease vaccines and intratumoral cancer-immunotherapy regimens. ([eleaflet.gsk.com](https://eleaflet.gsk.com/content/dam/cf-pharma/eleaflet/master/Shingrix%20PI%20eLeaflet%20IP04%28SI%29_approved%2025Oct2024_EL-0027842-06.pdf))
- Other names
- AS01 BAS-01 BAS 01 BAS01_BAdjuvant System AS01B
02
Targets
CholesterolCD2 (T-cell Surface Antigen CD2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on AS01B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS01B.